近年来，包括免疫检查点抑制在内的免疫疗法已经改变了癌症治疗方法，甚至为晚期疾病患者提供了新的、潜在的治疗选择。然而，只有少数患者获得长期缓解，并且对免疫检查点抑制的抵抗很常见。最近，唾液酸-Siglec 轴被提议作为一种新的免疫检查点，可以克服对当前免疫治疗方案的耐药性。在这篇综述中，我们总结了目前关于唾液酸-Siglec 相互作用在癌症免疫抑制中的作用的临床前知识，并讨论了阻断这一抑制途径以增强抗癌免疫力的潜在方法。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Immunotherapy, including immune checkpoint inhibition, has transformed cancer therapy in recent years, providing new and potentially curative options for patients with even advanced disease. However, only a minority of patients achieve long-lasting remissions, and resistance to immune checkpoint inhibition is common. Recently, the sialic acid-Siglec axis has been proposed as a new immune checkpoint that could overcome resistance to current immunotherapy options. In this review, we summarize the current preclinical knowledge about the role of the sialic acid-Siglec interaction in immune suppression in cancer and discuss potential approaches to block this inhibitory pathway to enhance anti-cancer immunity.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.